Massimo Di Maio, MD, on Niraparib and Best Supportive Care as Maintenance Therapy for Urothelial Cancer

Posted: Thursday, March 31, 2022

Massimo Di Maio, MD, of the University of Turin, discusses findings of the Meet-URO12 trial, which showed that maintenance niraparib plus best supportive care (BSC) did not prolong progression-free survival, compared with BSC alone, among patients with urothelial cancer that did not progress after first-line platinum-based chemotherapy.